Promega Signs Agreement with the Guangzhou Institute of Biomedicine and Health
News Apr 11, 2007
The agreement is designed to co-develop compound profiling solutions for small molecule and traditional Chinese medicine drug screening.
By combing the drug discovery expertise of GIBH with the biological assay expertise of Promega, the partnership is intended to deliver turnkey services to pharmaceutical companies interested in speeding up their lead discovery and lead optimization processes.
GIBH scientists will offer contract services designed to profile the biology of potential leads using the Promega suite of biological drug screening assays. Initial plans call for development of Cytochrome P450, Cytotoxicity, Kinase and GPCR profiling assays.
GIBH will use the assays both in house for own discovery programs as well as offer them on a contract basis to outside companies.
Ingestible Drug-Delivery Materials May Improve Patient Treatment ComplianceNews
Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.READ MORE
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE
Comments | 0 ADD COMMENT
International Conference and Exhibition on Nanomedicine and Nanotechnology
Nov 23 - Nov 24, 2017
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018